Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.28-0.47 (-4.00%)
At close: 04:00PM EDT
11.38 +0.10 (+0.89%)
After hours: 06:03PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close11.75
Open11.61
Bid11.08 x 1300
Ask11.95 x 800
Day's Range11.10 - 11.63
52 Week Range7.40 - 18.93
Volume349,762
Avg. Volume499,798
Market Cap606.028M
Beta (5Y Monthly)1.01
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CARA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cara Therapeutics, Inc.
    CARA: What does Argus have to say about CARA?CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $7.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Zacks

    Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

    Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Zacks

    Should You Buy Cara Therapeutics (CARA) Ahead of Earnings?

    Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Insider Monkey

    10 Medical Marijuana Stocks to Buy Now

    In this article, we discuss 10 medical marijuana stocks to buy now. If you want to see more stocks in this list, check out 5 Medical Marijuana Stocks to Buy Now. Medical Marijuana, also called medical Cannabis, is a herbal drug derived from plants of the genus Cannabis that is used as part of the […]

Advertisement
Advertisement